Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Confronting the Problem of AI Bias

Posted on June 18th, 2021 by

AI & Data

When thinking of artificial intelligence (AI), many people rely on cultural touchstones from science fiction films and TV. They might think of HAL, the calm-voiced AI from 2001: A Space Odyssey, or Data, the even-tempered android from Star Trek. We tend to imagine that artificial intelligence will be driven by reason, logic and facts – not by the emotions and prejudices that get us regular humans into trouble so often.

(more…)

An Update on Global Availability of COVID-19 Vaccines from Editor of The Lancet

Posted on June 11th, 2021 by

Pharma R&D

In the U.S., the COVID-19 vaccine roll-out has moved at a strong pace, with about half of Americans now having received at least one shot. While many of the most motivated people have been able to get vaccinated by now, plenty of others still have questions. They may wonder if the vaccines are safe in general, or safe for them personally if they have a particular condition. They may have been confronted with conflicting information about the efficacy of vaccines.

(more…)

4 Notable Life Sciences Trends from the Tech Trends Report

Posted on June 4th, 2021 by

AI & Data

The Future Today Institute has released its 2021 Tech Trends Report (14th Annual Edition), a comprehensive report on strategic trends that it anticipates will affect business, government, education, media and society in the coming year. We noted four trends discussed in the report’s Health, Medicine & Science section that will be of particular interest to those in the pharmaceutical and life sciences sectors.

(more…)

AI Disease Modeling Supports Precision Medicine for Cancer

Posted on June 1st, 2021 by

Pharma R&D

Precision medicine has offered a lot of hope for the treatment of cancer, as it makes it possible to tackle the multi-faceted disease with a more personalized, patient-specific approach. Meanwhile, researchers are also becoming increasingly interested in applications for artificial intelligence in the development of drugs and therapies. Could AI and precision medicine work together in the fight against cancer?

(more…)

phactMI: Delivering accurate drug information to point of care, part IV

Posted on May 26th, 2021 by

Medical Information

Part 4: How phactMI and Elsevier collaborated to deliver information to healthcare professionals

The Pharma Collaboration for Transparent Medical Information™ (phactMI) is a non-profit organization that seeks to improve the lives of patients by supporting the safe and effective use of medicines. One of their major goals is to make it easier for healthcare professionals to access unbiased, evidence-based medical information about medicinal products, allowing the HCPs to quickly and efficiently find answers to their questions so that they can make informed decisions for their patients. To achieve this goal, they partnered with Elsevier.

(more…)

Expert Forum Examines the Patent Content Expansion Plan for Reaxys

Posted on May 21st, 2021 by

Chemistry

User feedback is instrumental to the evolution of Reaxys. Not only in articulating what works and what is missing, but also in guiding the direction of newly developed capabilities to meet user information needs.

(more…)

  1. 1
  2. 2
  3. 3
  4. …
  5. 84

About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.